Literature DB >> 28596426

Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.

Adam T Hill1,2, Charles S Haworth3,2, Stefano Aliberti4, Alan Barker5, Francesco Blasi4, Wim Boersma6, James D Chalmers7, Anthony De Soyza8, Katerina Dimakou9, J Stuart Elborn10, Charles Feldman11, Patrick Flume12, Pieter C Goeminne13,14, Michael R Loebinger15, Rosario Menendez16, Lucy Morgan17, Marlene Murris18, Eva Polverino19, Alexandra Quittner20, Felix C Ringshausen21, Gregory Tino22, Antoni Torres19, Montserrat Vendrell23, Tobias Welte21, Rob Wilson15, Conroy Wong24, Anne O'Donnell25,26, Timothy Aksamit27,26.   

Abstract

There is a need for a clear definition of exacerbations used in clinical trials in patients with bronchiectasis. An expert conference was convened to develop a consensus definition of an exacerbation for use in clinical research.A systematic review of exacerbation definitions used in clinical trials from January 2000 until December 2015 and involving adults with bronchiectasis was conducted. A Delphi process followed by a round-table meeting involving bronchiectasis experts was organised to reach a consensus definition. These experts came from Europe (representing the European Multicentre Bronchiectasis Research Collaboration), North America (representing the US Bronchiectasis Research Registry/COPD Foundation), Australasia and South Africa.The definition was unanimously approved by the working group as: a person with bronchiectasis with a deterioration in three or more of the following key symptoms for at least 48 h: cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; haemoptysis AND a clinician determines that a change in bronchiectasis treatment is required.The working group proposes the use of this consensus-based definition for bronchiectasis exacerbation in future clinical research involving adults with bronchiectasis.
Copyright ©ERS 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28596426     DOI: 10.1183/13993003.00051-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  64 in total

Review 1.  Medical management of bronchiectasis.

Authors:  Anne E O'Donnell
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 2.  Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.

Authors:  Patrick A Flume; James D Chalmers; Kenneth N Olivier
Journal:  Lancet       Date:  2018-09-08       Impact factor: 79.321

3.  Integrative microbiomics in bronchiectasis exacerbations.

Authors:  Micheál Mac Aogáin; Jayanth Kumar Narayana; Pei Yee Tiew; Nur A'tikah Binte Mohamed Ali; Valerie Fei Lee Yong; Tavleen Kaur Jaggi; Albert Yick Hou Lim; Holly R Keir; Alison J Dicker; Kai Xian Thng; Akina Tsang; Fransiskus Xaverius Ivan; Mau Ern Poh; Martina Oriano; Stefano Aliberti; Francesco Blasi; Teck Boon Low; Thun How Ong; Brian Oliver; Yan Hui Giam; Augustine Tee; Mariko Siyue Koh; John Arputhan Abisheganaden; Krasimira Tsaneva-Atanasova; James D Chalmers; Sanjay H Chotirmall
Journal:  Nat Med       Date:  2021-04-05       Impact factor: 53.440

4.  Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry.

Authors:  Ashwin Basavaraj; Radmila Choate; Doreen Addrizzo-Harris; Timothy R Aksamit; Alan Barker; Charles L Daley; M Leigh Anne Daniels; Edward Eden; Angela DiMango; Kevin Fennelly; David E Griffith; Margaret M Johnson; Michael R Knowles; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Matthias A Salathe; Andreas Schmid; Byron Thomashow; Gregory Tino; Kevin L Winthrop
Journal:  Chest       Date:  2020-07-03       Impact factor: 9.410

5.  Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis.

Authors:  Simon Finch; Irena F Laska; Hani Abo-Leyah; Thomas C Fardon; James D Chalmers
Journal:  Chest       Date:  2019-11-12       Impact factor: 9.410

Review 6.  Diagnosis and management of non-cystic fibrosis bronchiectasis.

Authors:  Laura Macfarlane; Kartik Kumar; Thomas Scoones; Andrew Jones; Michael R Loebinger; Robert Lord
Journal:  Clin Med (Lond)       Date:  2021-11       Impact factor: 2.659

7.  Duration of antibiotic therapy in non-cystic fibrosis bronchiectasis.

Authors:  R Somayaji; C H Goss
Journal:  Curr Pulmonol Rep       Date:  2019-11-26

8.  Nutrition and Markers of Disease Severity in Patients With Bronchiectasis.

Authors:  Katherine A Despotes; Radmila Choate; Doreen Addrizzo-Harris; Timothy R Aksamit; Alan Barker; Ashwin Basavaraj; Charles L Daley; Edward Eden; Angela DiMango; Kevin Fennelly; Julie Philley; Margaret M Johnson; Pamela J McShane; Mark L Metersky; Anne E O'Donnell; Kenneth N Olivier; Matthias A Salathe; Andreas Schmid; Byron Thomashow; Gregory Tino; Kevin L Winthrop; Michael R Knowles; Mary Leigh Anne Daniels; Peadar G Noone
Journal:  Chronic Obstr Pulm Dis       Date:  2020-10

9.  Inhaled Corticosteroid Therapy in Bronchiectasis is Associated with All-Cause Mortality: A Prospective Cohort Study.

Authors:  Kjell E J Håkansson; Katrine Fjaellegaard; Andrea Browatzki; Melda Dönmez Sin; Charlotte Suppli Ulrik
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-07-16

10.  Small Airway Disease and Emphysema Are Associated with Future Exacerbations in Smokers with CT-derived Bronchiectasis and COPD: Results from the COPDGene Cohort.

Authors:  Diego Jose Maselli; Andrew Yen; Wei Wang; Yuka Okajima; Wojciech R Dolliver; Christina Mercugliano; Antonio Anzueto; Marcos I Restrepo; Timothy R Aksamit; Ashwin Basavaraj; Stefano Aliberti; Kendra A Young; Gregory L Kinney; J Michael Wells; Raúl San José Estépar; David A Lynch; Alejandro A Diaz
Journal:  Radiology       Date:  2021-06-22       Impact factor: 29.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.